2022. The Evidence and Clinical Rationale for the Use of JAK Inhibitors in the Management of AD . Actualité en allergologie et en immunologie au Canada. 2, s11 (nov. 2022), 3–11. DOI:https://doi.org/10.58931/cait.2022.2s1148.